CN111269177A - Crystal forms of quinolinone compounds - Google Patents
Crystal forms of quinolinone compounds Download PDFInfo
- Publication number
- CN111269177A CN111269177A CN201911195230.7A CN201911195230A CN111269177A CN 111269177 A CN111269177 A CN 111269177A CN 201911195230 A CN201911195230 A CN 201911195230A CN 111269177 A CN111269177 A CN 111269177A
- Authority
- CN
- China
- Prior art keywords
- form iii
- crystalline form
- ray powder
- degrees
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Test sample | AUClast(h*ng/ml) | Cmax(ng/ml) | Tmax(h) |
Crystal form III | 7090 | 1910 | 1.33 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911195230.7A CN111269177B (en) | 2019-11-28 | 2019-11-28 | Crystal forms of quinolinone compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911195230.7A CN111269177B (en) | 2019-11-28 | 2019-11-28 | Crystal forms of quinolinone compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111269177A true CN111269177A (en) | 2020-06-12 |
CN111269177B CN111269177B (en) | 2023-05-09 |
Family
ID=70995312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911195230.7A Active CN111269177B (en) | 2019-11-28 | 2019-11-28 | Crystal forms of quinolinone compounds |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111269177B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021104353A1 (en) * | 2019-11-28 | 2021-06-03 | 广东东阳光药业有限公司 | Crystal form of quinolinone compound and use thereof |
CN115010662A (en) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | Crystal form of quinolinone compound and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
CN105384687A (en) * | 2014-09-02 | 2016-03-09 | 广东东阳光药业有限公司 | Quinolinone compound and application thereof in drugs |
CN108069952A (en) * | 2016-11-08 | 2018-05-25 | 广东东阳光药业有限公司 | It quinolinones compound and its is applied in drug |
CN108341777A (en) * | 2017-01-23 | 2018-07-31 | 四川科伦博泰生物医药股份有限公司 | Compound of isobioquin group and its application |
-
2019
- 2019-11-28 CN CN201911195230.7A patent/CN111269177B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
CN105384687A (en) * | 2014-09-02 | 2016-03-09 | 广东东阳光药业有限公司 | Quinolinone compound and application thereof in drugs |
CN108069952A (en) * | 2016-11-08 | 2018-05-25 | 广东东阳光药业有限公司 | It quinolinones compound and its is applied in drug |
CN108341777A (en) * | 2017-01-23 | 2018-07-31 | 四川科伦博泰生物医药股份有限公司 | Compound of isobioquin group and its application |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021104353A1 (en) * | 2019-11-28 | 2021-06-03 | 广东东阳光药业有限公司 | Crystal form of quinolinone compound and use thereof |
CN115010662A (en) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | Crystal form of quinolinone compound and application thereof |
WO2022184159A1 (en) * | 2021-03-05 | 2022-09-09 | 广东东阳光药业有限公司 | Crystal form of quinolinone compound and use thereof |
CN115010662B (en) * | 2021-03-05 | 2023-12-08 | 广东东阳光药业股份有限公司 | Crystal forms of quinolinone compounds and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111269177B (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110577534B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110922407B (en) | Crystal forms of benzoylaminopyridine derivatives and uses thereof | |
CN110577535B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577538B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577540B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577541B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577539B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577533B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577536B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN110577537B (en) | Salts of benzoylaminopyridine derivatives and their use in medicine | |
CN111269177B (en) | Crystal forms of quinolinone compounds | |
CN111269176A (en) | Crystal forms of quinolinone compounds | |
CN111269178A (en) | Crystal forms of quinolinone compounds | |
CN113549067B (en) | Crystal forms of dihydronaphthyridine compounds and application thereof | |
CN112851581B (en) | Crystal form of quinolinone compound and application thereof | |
CN115010662B (en) | Crystal forms of quinolinone compounds and application thereof | |
CN113549066B (en) | Crystal forms of dihydronaphthyridine compounds and application thereof | |
CN115368303A (en) | Salt of quinolinone compound and use thereof | |
CN115010664A (en) | Crystal form of quinolinone compound and application thereof | |
CN115368304A (en) | Salt of quinolinone compound and use thereof | |
CN115368305A (en) | Salt of quinolinone compound and use thereof | |
CN115010663A (en) | Crystal form of quinolinone compound and application thereof | |
EP4317133A1 (en) | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof | |
CN115368302A (en) | Salt of quinolinone compound and use thereof | |
CN112851640A (en) | Sulfate of pyrimidine benzamide compound and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200928 Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant after: SUNSHINE LAKE PHARMA Co.,Ltd. Address before: Room 1, 14 / F, Yuexiu building, 160-174 Lockhart Road, Wanchai, Hong Kong, China Applicant before: North South brothers pharmaceutical investment Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200612 Assignee: Nianyan Pharmaceutical (Shanghai) Co.,Ltd. Assignor: SUNSHINE LAKE PHARMA Co.,Ltd. Contract record no.: X2021980013023 Denomination of invention: Crystal forms of quinolone compounds License type: Exclusive License Record date: 20211124 |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |